Mercaptopurine
- Generic Name
- Mercaptopurine
- Brand Names
- Purixan, Xaluprine (previously Mercaptopurine Nova Laboratories)
- Drug Type
- Small Molecule
- Chemical Formula
- C5H4N4S
- CAS Number
- 50-44-2
- Unique Ingredient Identifier
- PKK6MUZ20G
- Background
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
- Indication
For remission induction and maintenance therapy of acute lymphatic leukemia.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Promyelocytic Leukemia, Autoimmune Hepatitis, Crohn's Disease (CD), Lymphoblastic Lymphoma, Ulcerative Colitis
- Associated Therapies
- -
Phase III Trial in Acute Promyelocytic Leukemia Patients
- Conditions
- Interventions
- First Posted Date
- 2007-06-05
- Last Posted Date
- 2022-10-12
- Target Recruit Count
- 276
- Registration Number
- NCT00482833
- Locations
- 🇦🇹
Universitätsklinik Innsbruck Hämatologie Onkologie, Innsbruck, Austria
🇦🇹Krankenhaus der Barmherzigen Schwestern Linz, Linz, Austria
🇦🇹Universitätsklinik für Innere Medizin III Salzburg, Salzburg, Austria
ALL Adult Consortium Trial: Adult ALL Trial
- Conditions
- Interventions
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 112
- Registration Number
- NCT00476190
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Children's Hospital of Boston, Boston, Massachusetts, United States
Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2019-02-15
- Target Recruit Count
- 470
- Registration Number
- NCT00458848
- Locations
- 🇮🇹
Ospedale S. Donato, Arezzo, Italy
🇮🇹S.G. Moscati Hospital, Avellino, Italy
🇮🇹Ospedale Binaghi, Cagliari, Italy
Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: asparaginaseDrug: cyclophosphamideDrug: cytarabineDrug: daunorubicin hydrochlorideDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: ifosfamideDrug: etoposideDrug: mercaptopurineDrug: methotrexateDrug: prednisoneDrug: thioguanineDrug: vincristine sulfateDrug: vindesineRadiation: radiation therapy
- First Posted Date
- 2007-02-01
- Last Posted Date
- 2013-05-29
- Lead Sponsor
- University Hospital Schleswig-Holstein
- Target Recruit Count
- 4559
- Registration Number
- NCT00430118
- Locations
- 🇦🇹
LKH Leoben, Leoben, Austria
🇦🇹Landeskrankenhaus Feldkirch, Feldkirch-Tisis, Austria
🇦🇹Universitaet Kinderklinik, Graz, Austria
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
- Conditions
- Interventions
- Other: Laboratory Biomarker AnalysisDrug: CyclophosphamideDrug: AsparaginaseDrug: Daunorubicin HydrochlorideDrug: CytarabineDrug: MercaptopurineDrug: Leucovorin CalciumDrug: DexamethasoneDrug: PegaspargaseDrug: Doxorubicin HydrochlorideDrug: MethotrexateDrug: NelarabineDrug: PrednisoneDrug: Vincristine SulfateRadiation: Radiation TherapyDrug: Thioguanine
- First Posted Date
- 2006-12-05
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1895
- Registration Number
- NCT00408005
- Locations
- 🇺🇸
Scott and White Memorial Hospital, Temple, Texas, United States
🇺🇸Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
Treatment of Acute Lymphoblastic Leukemia in Children
- Conditions
- Interventions
- Drug: asparaginaseDrug: cyclophosphamideDrug: cytarabineDrug: dexamethasoneDrug: dexrazoxane hydrochlorideDrug: doxorubicin hydrochlorideDrug: leucovorin calciumDrug: etoposideDrug: mercaptopurineDrug: methotrexateDrug: methylprednisoloneDrug: pegaspargaseDrug: prednisoloneDrug: therapeutic hydrocortisoneDrug: vincristine sulfateRadiation: radiation therapy
- First Posted Date
- 2006-11-17
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 800
- Registration Number
- NCT00400946
- Locations
- 🇨🇦
McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇺🇸Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States
🇨🇦Centre de Recherche du Centre Hospitalier de l'Universite Laval, Sainte Foy, Quebec, Canada
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 275
- Registration Number
- NCT00381680
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
🇺🇸Childrens Memorial Hospital, Chicago, Illinois, United States
Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2006-06-23
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Target Recruit Count
- 550
- Registration Number
- NCT00343369
- Locations
- 🇩🇪
Dr. von Haunersches Kinderspital der Universitaet Muenchen, Munich, Germany
🇩🇪Kreskrankenhaus Kinderabteilung, Heide, Germany
🇩🇪Universitaets - Kinderklinik, Leipzig, Germany
Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia
- Conditions
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama, United States
Prednisolone or Dexamethasone Combined With Chemotherapy in Treating Young Patients With Newly Diagnosed Lymphoblastic Lymphoma
- Conditions
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- Children's Cancer and Leukaemia Group
- Target Recruit Count
- 600
- Registration Number
- NCT00275106
- Locations
- 🇬🇧
Addenbrooke's Hospital, Cambridge, England, United Kingdom
🇬🇧Royal Manchester Children's Hospital, Manchester, England, United Kingdom
🇩🇪Kinderklinik, Giessen, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.